Targeted Therapy Based on Peptide– Drug Conjugates

	Targeted Therapy Based on Peptide– Drug Conjugates
Advances in Pharmacology and Therapeutics Journal
Volume 5, Issue 4 - Serial Number 11, June 2026, Pages 247-248 PDF (171.17 K)
Document Type: Editorial Article
DOI: 10.18502/aptj.v5i4.21765
Authors
Marzieh Lotfi; Seyed Hossein Shahcheraghi^*
Abstract
*Abstract* Peptide–drug conjugates (PDCs) are useful in new targeted therapy, especially in cancer. It has also been established that proteases are highly expressed in cancer types. These enzymes can cleave the linker, releasing the drugs as a key payload within the tumor. Therefore, overexpression of cathepsins in tumor environments is a favorable characteristic for targeted cancer therapy. The linker must exhibit stability in circulation to avoid undefined cargo release. Releasing with no goal can cause some problems with the enhancement of toxins, which can lead to hazardous or even incurable side effects. Payloads as cytotoxic agents usually show low IC50 values and high toxicity. Two payloads applied within PDC types include Taxol and Daunorubicin.
Keywords
Peptide–drug conjugates; Targeted therapy; Cancer

Statistics Article View: 5 PDF Download: 7